Open AccessBudget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
Author(s) -
Patrizia Berto,
Marco Bellone,
Alice Sabinot,
Carmine Pinto,
Massimo Martino,
Daniele Generali,
Pier Luigi Carriero,
Maria Domenica Sanna
Publication year - 2022
Publication title -
farmeconomia/farmeconomia e percorsi terapeutici
Language(s) - English
Resource type - Journals
eISSN - 1721-6923
pISSN - 1721-6915
DOI - 10.7175/fe.v23i1.1516
Subject(s) - pegfilgrastim , biosimilar , medicine , febrile neutropenia , filgrastim , formulary , intensive care medicine , pharmacy , neutropenia , chemotherapy , pharmacology , nursing
Current Italian guidelines recommend prophylaxis with granulocyte colony-stimulating factors (G-CSFs) to reduce the risk of chemotherapy-induced febrile neutropenia (FN). The availability of G-CSF biosimilars represents an opportunity for savings in the Italian National Healthcare Service (NHS) delivery of care.OBJECTIVE: To assess the cost saving potential associated with the introduction of pegfilgrastim biosimilars to local formularies, compared to the current G-CSF standard practice in Italy.METHODS: A budget impact model was developed to compare the current standard practice of long-acting (LA) and short-acting (SA) G-CSFs use, with a future scenario in which the market share of LA G-CSFs grows due to the more advantageous administration schedule and price of pegfilgrastim biosimilar. The analysis included G-CSF treatment schedules, drug acquisition costs and costs of patient management including hospitalization and ambulatory care.RESULTS: The introduction of pegfilgrastim biosimilar resulted in cumulative 3-year cost savings of € 59,650 and € 41,539 for FN prophylaxis in a potential cohort of 1000 patients with solid tumors and lymphomas, respectively.CONCLUSIONS: The results indicate that the introduction of pegfilgrastim biosimilar is potentially associated with substantial cost savings for the Italian healthcare system.